Online inquiry

IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6360MR)

This product GTTS-WQ6360MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets MSTN gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005259.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2660
UniProt ID O14793
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MSTN, CSL-362-AML(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ6360MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3776MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ13438MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ12957MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PDL 192
GTTS-WQ10575MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ6107MR IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA COR-001
GTTS-WQ8182MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HL161
GTTS-WQ702MR IVTScrip™ mRNA-Anti-IL17A&TNF, A-1230717(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA A-1230717
GTTS-WQ1014MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-383
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW